PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.
PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
|Alternate Symbols: ||CACNN; Cav2.2|
|PharmGKB Accession Id:||PA26008|
|Cytogenetic Location:||chr9 : q34.3 - q34.3|
|GP mRNA Boundary†:||chr9 : 140772241 - 141019076|
|GP Gene Boundary†:||chr9 : 140762241 - 141022076|
UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.View on UCSC Browser
PharmGKB Curated Pathways
Pathways created internally by PharmGKB based primarily on literature evidence.
Beta-agonist/Beta-blocker Pathway, Pharmacodynamics
Simplified pharmacodynamic pathway of drug action on beta 2 adrenergic receptor in a stylized airway cell.
Celecoxib Pathway, Pharmacodynamics
Stylized cell depicting the mechanism of action of celecoxib and candidate genes interacting with celecoxib and involved in the regulation of cell cycle, apoptosis and angiogenesis by celecoxib.
Sympathetic Nerve Pathway (Neuroeffector Junction)
Simplified diagram of a sympathetic neuroeffector junction displaying genes which may be involved.
Sympathetic Nerve Pathway (Pre- and Post- Ganglionic Junction)
Simplified diagram of a sympathetic neuronal junction displaying genes involved in neurotransmitter biosynthesis in response to neuronal stimulation.
Publications related to CACNA1B: 6
The following icons indicate that data of a certain type is available:
- DG Dosing Guideline information is available
- DL Drug Label information is available
- CA High-level Clinical Annotation is available
- VA Variant Annotation is available
- VIP VIP information is available
- PW Pathway is available
[ close ]
||Epigenomic mapping and effect sizes of noncoding variants associated with psychotropic drug response. Pharmacogenomics. 2015. Higgins Gerald A, et al.|
||Rare variants in neuronal excitability genes influence risk for bipolar disorder. Proceedings of the National Academy of Sciences of the United States of America. 2015. Ament Seth A, et al.|
||Masters or slaves? Vesicle release machinery and the regulation of presynaptic calcium channels. Cell calcium. 2005. Jarvis Scott E, et al.|
||Presynaptic Ca2+ channels: a functional patchwork. Trends in neurosciences. 2003. Reid Christopher A, et al.|
||Calcium-dependent inhibition of L, N, and P/Q Ca2+ channels in chromaffin cells: role of mitochondria. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2001. Hernandez-Guijo J M, et al.|
||Calcium channel subtypes differ at two types of cholinergic synapse in lumbar sympathetic neurones of guinea-pigs. The Journal of physiology. 1999. Ireland D R, et al.|